Dr. Kari M. Rosenkranz, MD

Dr. Rosenkranz practices at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health.

Dr. Rosenkranz's NPI, 1326156761, was assigned on August 27, 2006. Dr. Rosenkranz graduated from Albany Medical College of Union University in 1999. Dr. Rosenkranz holds New Hampshire license 11489.

Dr. Rosenkranz's primary practice is Dartmouth Hitchcock Medical Center, at 1 Medical Center Drive, Lebanon, NH 03756 in Grafton County. The practice phone is (603) 650-5000.

Dr. Rosenkranz's primary practice is Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, part of Dartmouth-Hitchcock Health. Dr. Rosenkranz is also affiliated with Cheshire Medical Center. The medical group on file is Dartmouth Hitchcock Medical Center. Dmand AI also links Dr. Rosenkranz to 1 more medical group, named with a free account. Dr. Rosenkranz's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenkranz practices, 2 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Rosenkranz's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Rosenkranz is licensed in New Hampshire.

CMS data shows 164 Medicare services from Dr. Rosenkranz across 6 procedure codes in 2024, for 113 Medicare patients. Medicare paid $34,805 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Dr. Rosenkranz in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have cancer, and 57% have high blood pressure. 10% are also on Medicaid. Their average risk score is 0.99, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rosenkranz's median patient age at 58, with 96% women.

In 2024, Dr. Rosenkranz wrote 38 Medicare Part D claims for 16 patients. 100% of them were for generic drugs. CMS names the drug for 29 of them, across 1 drug with 11 or more claims each, at $389 in total drug cost. In 2023, CMS named 22 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Rosenkranz for performance year 2024, reported as part of a group. Dr. Rosenkranz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 29 procedures of mastectomy by Dr. Rosenkranz, more than 86% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 41 papers to Dr. Rosenkranz, published from 2012 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Mastectomy, Segmental and Mastectomy. Dr. Rosenkranz has published most often in Ann Surg Oncol. Dr. Rosenkranz's most frequent co-authors are Richard Joseph Barth, MD, Judy C. Boughey, MD and Laurie W. Cuttino, MD.

Dmand AI links Dr. Rosenkranz to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 13 general payments to Dr. Rosenkranz from 3 drug and device companies from 2017 to 2024. Consulting fees make up the largest share, 77% of the total. 3D Systems paid the most, $6,111.

Dr. Rosenkranz graduated from Albany Medical College of Union University in 1999.